Seagen's GenAI journey: Revolutionizing R&D from molecule to market

The intersection of cutting-edge technology and human need defines the future of pharmaceutical innovation. This webinar presents the collaborative journey of Seagen (now part of Pfizer) and Thoughtworks in applying Generative AI to transform research and development—from molecule to market. Through a case study grounded in real-world impact, the session demonstrates how a human-centered, strategically governed approach to AI can accelerate discovery, improve data usability, and support researchers in addressing one of the most complex challenges in medicine: cancer. Key topics include: – The growing human and economic burden of cancer, and the increasing complexity and cost of bringing new therapies to market. – Seagen’s advancements in Antibody Drug Conjugates (ADCs) and the scientific, regulatory, and operational challenges surrounding their development. – The strategic design and implementation of a Generative AI-powered research assistant to surface insights, aggregate multidisciplinary data, and support scientific decision-making. – A framework for responsible AI adoption—centered on user experience, cognitive bias mitigation, change enablement, and continuous learning. – An enterprise-level GenAI strategy focused on value-driven prioritization, lean delivery models, and robust data foundations. – Illustrative use cases of Generative AI in R&D, from interpreting historical decisions to automating code generation and data visualization. – Application of product thinking to data, resulting in AI-recommended, interoperable data products with significant reductions in lead time. – Integration of compliance and governance by design, ensuring regulatory alignment and ethical safeguards are built into each stage of development. This session is relevant for technology and R&D leaders in the pharmaceutical and life sciences industries seeking to understand how Generative AI can be applied at scale to enable innovation, reduce friction, and improve outcomes.